ABBVIE
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 2013-01-01
- Employees
- -
- Market Cap
- $346B
- Website
- http://www.abbvie.com
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder
- Conditions
- Generalized Anxiety Disorder (GAD)
- Interventions
- First Posted Date
- 2025-02-26
- Last Posted Date
- 2025-07-04
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 315
- Registration Number
- NCT06846320
- Locations
- 🇺🇸
Elixia, LLC /ID# 267815, Springfield, Massachusetts, United States
🇺🇸University of Alabama - Huntsville Regional Medical Campus /ID# 267818, Huntsville, Alabama, United States
🇺🇸Ima Clinical Research Phoenix (Alea) /ID# 275737, Phoenix, Arizona, United States
An Observational Study to Evaluate Effectiveness and Safety of Upadacitinib in Chinese Adult Participants With Moderate to Severely Active Ulcerative Colitis (UC)
- Conditions
- Ulcerative Colitis
- First Posted Date
- 2025-02-21
- Last Posted Date
- 2025-05-31
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 80
- Registration Number
- NCT06838845
- Locations
- 🇨🇳
The First Affiliated Hospital, Sun-Yat Sen University /ID# 272997, Guangzhou, Guangdong, China
🇨🇳The Sixth Affiliated Hospital of Sun Yat-sen University /ID# 274753, Guangzhou, Guangdong, China
🇨🇳The Second Affiliated Hospital Of Zhengzhou University /ID# 274754, Zhengzhou, Henan, China
A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL)
- Conditions
- Glabellar Lines
- Interventions
- First Posted Date
- 2025-02-19
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 126
- Registration Number
- NCT06834789
- Locations
- 🇺🇸
Investigate MD /ID# 270771, Scottsdale, Arizona, United States
🇺🇸Marcus Facial Plastic Surgery /ID# 270770, Redondo Beach, California, United States
🇺🇸Skin Research Institute LLC /ID# 270831, Coral Gables, Florida, United States
Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma
- Conditions
- Diffuse Large B-cell LymphomaFollicular Lymphoma
- First Posted Date
- 2025-02-17
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 700
- Registration Number
- NCT06830759
- Locations
- 🇨🇦
Cross Cancer Institute /ID# 271504, Edmonton, Alberta, Canada
🇨🇦Health Sciences North /ID# 274738, Sudbury, Ontario, Canada
🇬🇷Evangelismos Hospital /ID# 272736, Athens, Attiki, Greece
A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma
- Conditions
- Primary Open Angle Glaucoma
- First Posted Date
- 2025-02-12
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 130
- Registration Number
- NCT06822738
- Locations
- 🇺🇸
University Of Colorado - Anschutz Medical Campus /ID# 269947, Aurora, Colorado, United States
🇺🇸UT Southwestern Medical Center /ID# 268571, Dallas, Texas, United States
🇺🇸Arizona Advanced Eye Research Institute /ID# 268363, Glendale, Arizona, United States
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2025-02-11
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 390
- Registration Number
- NCT06820463
- Locations
- 🇦🇺
Macquarie University /ID# 271514, Sydney, New South Wales, Australia
🇨🇳National Taiwan University Hospital /ID# 269717, Taipei City, Taipei, Taiwan
🇺🇸Yale New Haven Hospital /ID# 270565, New Haven, Connecticut, United States
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
- First Posted Date
- 2025-02-05
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 420
- Registration Number
- NCT06810505
- Locations
- 🇺🇸
Rehabilitation & Neurological Services /ID# 270782, Huntsville, Alabama, United States
🇺🇸Preferred Research Partners /ID# 270389, Little Rock, Arkansas, United States
🇺🇸Preferred Research Partners /ID# 270419, Little Rock, Arkansas, United States
Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
- Conditions
- Menstrual Migraine (MM)
- Interventions
- First Posted Date
- 2025-02-04
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 430
- Registration Number
- NCT06806293
- Locations
- 🇨🇳
Chinese PLA General Hospital /ID# 267141, Beijing, Beijing, China
🇨🇳Nanfang Hospital - Southern Medical University /ID# 268510, Guangzhou, Guangdong, China
🇨🇳Hebei General Hospital /ID# 267663, Shijiazhuang, Hebei, China
A Study to Assess Adverse Events and Effectiveness of OnabotulinumtoxinA Intramuscular Injections for the Change of Moderate to Severe Forehead Lines in Adult Participants
- Conditions
- Forehead Lines
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-01-27
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 150
- Registration Number
- NCT06794866
- Locations
- 🇯🇵
Hiroshima Station Clinic /ID# 268467, Hiroshima-Shi, Hiroshima, Japan
🇯🇵Kotoni Tower Skin And Cosmetic Surgery Clinic /ID# 268460, Sapporo, Hokkaido, Japan
🇯🇵Tokai University Hospital /ID# 268496, Isehara, Kanagawa, Japan
A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVÉDERM® Products, KYBELLA, CoolSculpting Elite and SkinMedica Products
- Conditions
- Facial Contouring
- Interventions
- Device: JUVÉDERMDevice: CoolSculpting Elite SystemOther: SkinMedica Products
- First Posted Date
- 2025-01-20
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 100
- Registration Number
- NCT06783621
- Locations
- 🇺🇸
Center for Dermatology and Dermatologic Surgery /ID# 270390, Washington, District of Columbia, United States
🇺🇸Marcus Facial Plastic Surgery /ID# 270408, Redondo Beach, California, United States
🇺🇸Pacific Clinical Innovations /ID# 270414, Vista, California, United States